Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | PHASE1 | COMPLETED | 41 | — | — | May 21, 2018 | Sep 23, 2019 | Apr 5, 2024 | 7 | United States, Canada +1 |
Assessment of frequency \& severity of adverse events
Determine objective response rate (ORR)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Multiple dose levels of MSC-1 treatment once every 3 weeks |
| Dose Expansion | EXPERIMENTAL | MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks |
| Name | Type | Description |
|---|---|---|
| MSC-1 | BIOLOGICAL | humanized monoclonal antibody for intravenous administration |
Inclusion Criteria (All patients): * Confirmed Advanced Unresectable Solid Tumor * Measurable disease by RECIST 1.1 by CT or MRI * Documented disease progression on or following last line of therapy * Archival tumor sample for submission * ECOG performance status 0 or 1 * Resolution of all acute, r...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |